You've learned that you have diffuse large B-cell lymphoma (DLBCL). What happens now? A cancer diagnosis can feel overwhelming. You might not know what to do first. Start by having a conversation ...

Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy ...

“RT is an aggressive lymphoma that develops in a patient with RT, most commonly a diffuse large B-cell lymphoma [DLBCL],” said CLL and lymphoma specialist Erin M. Parry, MD, PhD, of Dana ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

Researchers recently concluded that the care received by patients treated by the Veterans Health Administration for diffuse large B-cell lymphoma met the standard of care across races and ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Long-term data gathered from the TRANSCEND NHL trial have shown that this treatment approach can significantly improve survival.

Final guidance (PDF) published today recommends Breyanzi (lisocabtagene maraleucel or liso-cel) as an option for treating people with large B-cell lymphoma when their cancer has either not ...